CO-D THERAPEUTICS

Co-D Therapeutics' mission is to aggressively develop its lead product Triolimus to treat multiple types of cancer. We seek to position Co-D as a leader in the evolving field of nano-medicine drug combinations for cancer treatment... Co-D Therapeutics, Inc. is a preclinical stage biopharmaceutical company based in Madison, Wisconsin. Co-D is an innovative drug development company dedicated to developing first-in-class combination nano-medicines with high safety profiles to treat cancer. Co-D's nanotechnology based polymeric micelle delivery system enables the formulation and combinatorial delivery of multiple anticancer agents in a single novel therapeutic. This approach eliminates toxic carriers, permits safe dose-escalation and facilitates multi-drug deliver thereby maximizing the therapeutic index... We anticipate that Co-D's platform technology will generate multiple products in the future. Co-D is seeking to establish strategic partnerships that are aligned with our business..

Also known as: Co-D, Co-D Therapeutics, Inc.

Primary location: Madison United States